pISSN 2234-3806eISSN 2234-3814
Table. 1.
Characteristics of the patients and TDM data
| Characteristic | Value |
|---|---|
| N | 54 |
| Male sex, N (%) | 26 (48.1) |
| Age, yr | 71.5 (59, 81) |
| ≥ 65 yr, N (%) | 34 (63.0) |
| Body weight, kg | 56.7 (48.8, 65.0) |
| Height, cm | 160.5 (154.9, 170.0) |
| BSA, m2 | 1.58 (1.46, 1.71) |
| BMI, kg/m2 | 21.8 (19.6, 24.2) |
| Albumin, g/L | 29 (27, 33) |
| Complicated infections |
34 (63.0) |
| MRSA infections, N (%) | 9 (16.7) |
| Complicated MRSA infections, N (%) | 8 (14.8) |
| Serum creatinine, mg/dL | |
| 1st TDM occasion | 0.53 (0.45, 0.66) |
| 2nd TDM occasion | 0.52 (0.45, 0.67) |
| eCLcr |
|
| 1st TDM occasion | 100 (62, 145) |
| 2nd TDM occasion | 97 (69, 137) |
| eGFR |
|
| 1st TDM occasion | 104 (86, 119) |
| 2nd TDM occasion | 106 (89, 119) |
| Daily vancomycin dose per weight, mg/kg | |
| 1st TDM occasion | 30.8 (25.8, 37.7) |
| 2nd TDM occasion | 38.0 (24.5, 53.5) |
| Single vancomycin dose, mg | |
| 1st TDM occasion | 800 (662.5, 1000) |
| 2nd TDM occasion | 650 (600, 800) |
| Vancomycin dosing interval, N (1st/2nd) | |
| 4 hr | 1/7 |
| 6 hr | 2/13 |
| 8 hr | 7/15 |
| 12 hr | 41/17 |
| 24 hr | 3/2 |
| N doses before 1st trough sampling | 5 (3.3, 7.8) |
| Time gap from 1st dose to trough sampling, hr | |
| 1st trough sampling | 60.0 (47.6, 72.0) |
| 2nd trough sampling | 167.8 (132.5, 228.0) |
| Measured vancomycin trough concentration, mg/L | |
| 1st TDM set | 11.6 (6.8, 16.8) |
| 2nd TDM set | 18.1 (15.1, 20.7) |
| Measured vancomycin peak concentration, mg/L | |
| 1st TDM set | 25.9 (21.1, 33.3) |
| 2nd TDM set | 26.7 (22.8, 34.6) |
*Number (%) or median (Q1, Q3); †Complicated infections such as bacteremia, endocarditis, osteomyelitis, and CNS infections including meningitis and pneumonia; ‡Calculated using the Cockcroft–Gault equation; §Calculated using the CKD-EPI equation.
Abbreviations: BMI, body mass index; BSA, body surface area; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CNS, central nervous system; eCLcr, estimated creatinine clearance; eGFR, estimated glomerular filtration rate; MRSA, methicillin-resistant
Ann Lab Med 2023;43:554~564 https://doi.org/10.3343/alm.2023.43.6.554
© Ann Lab Med